Europe is home to many life sciences companies, so IP regimes throughout the continent’s jurisdictions need to provide cost-effective, speedy and certain litigation environments if patent disputes are to be satisfactorily settled.
LSIPR talks to Thomas Friede and Johannes Heselberger about why Germany fits this mould.
LSIPR: What are the advantages of litigating a life sciences patent in Germany?
Thomas Friede: I believe that the litigation procedure in Germany is an advantage. It is a very streamlined procedure, which is basically an exchange of written briefs—usually two rounds— before an oral hearing. The oral hearing is very condensed and focused. Even in a large case, a hearing would only be four or five hours long. If that is compared to a full trial in the US or the UK, it’s a fraction of the time and therefore it costs less.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
patent litigation, patent disputes, Germany
